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Abstract
Background: Chronic fatigue syndrome (CFS) presents a challenge for patients, health care providers,
and health insurance groups because of its incapacitating nature, unknown cause, and poorly understood
prognosis. We conducted a longitudinal population-based study to characterize the clinical course of CFS.
Methods: Sixty-five CFS subjects were identified from a random-digit-dialing survey of Wichita, Kansas
residents and followed for up to 3 years. We evaluated changes in CFS classification (partial or total
remission, alternative medical or psychiatric diagnoses), CFS case-defining criteria, wellness scores, hours
of activities and sleep, and treatments used to reduce fatigue. Associations between risk factors and
outcomes were determined by use of logistic regression and generalized estimating equations models.
Results: Only 20%-33% of the subjects were classified as having CFS at follow-up, 56.9% ever experienced
partial or total remission, 10% sustained total remission, and 23.1% received alternative diagnoses, of
which 20% were sleep disorders. Higher fatigue severity scores and total number of symptoms were
negatively associated with ever remitting. Duration of illness ≤ 2 years was positively associated with
sustained remission. Unrefreshing sleep persisted in at least 79% of the subjects across all periods but, as
with most of the CFS symptoms, tended to be less frequent over time. The number of activities affected
by fatigue decreased over time, while wellness scores increased. At any follow-up, more than 35% of
subjects reporting reduced fatigue used complementary and alternative medicine therapies, and of those
subjects, at least 50% thought these therapies were responsible for reducing their fatigue.
Conclusions: The clinical course of CFS was characterized by an intermittent pattern of relapse and
remission. Remission rates documented by our population-based study were similar to those reported in
clinical studies. Shorter illness duration was a significant predictor of sustained remission, and thus early
detection of CFS is of utmost importance. The persistence of sleep complaints and identification of sleep
disorders suggest that CFS subjects be evaluated for sleep disturbances, which could be treated.
Background
Chronic fatigue syndrome (CFS) is a debilitating illness
that causes substantial reduction in previous levels of pro-
fessional, recreational, social, or educational activities [1].
CFS presents a challenge for patients, health care provid-
ers, and health insurance groups because of its incapaci-
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tating nature, unknown cause, and poorly understood
clinical course. A systematic review [2] of prospective
studies found that 0%-37% (median = 6%) of adult CFS
patients recovered, and 6%-63% (median = 35%)
improved over time. Patients who recovered or improved
were younger, did not have a co-morbid psychiatric disor-
der, and did not believe that the illness was due to a phys-
ical cause. More recent estimates of recovery and
improvement are similar [3–6] (Table 1 [see Additional
file: 1]). Short duration predicted a higher likelihood of
recovery among patients enrolled in a surveillance system
[4] but was not associated with recovery in severely ill
patients selected from a CFS clinic [5] or from a CFS
research registry [6]. All of these studies were conducted in
clinical settings and thus involved people who were sick
enough and had sufficient resources to seek and obtain
medical care. In addition, most of the studies involved
patients from specialty clinics at tertiary care medical cent-
ers who have been triaged or whose diagnosis was contin-
uously supported by the health care system.
The objective of our study was to characterize the clinical
course of CFS in the general population. We identified
and followed CFS subjects from Wichita, Kansas for up to
3 years. We evaluated changes in CFS classification, case-
defining criteria [1], wellness scores, hours of activities
and sleep, and treatment use. We also determined associ-




This study adhered to human experimentation guidelines
of the U.S. Department of Health and Human Services. All
participants were volunteers who gave informed consent.
In 1997, we conducted a random-digit-dialing survey to
estimate the prevalence of CFS and other fatiguing ill-
nesses in Wichita, Kansas [7]. Briefly, a screening tele-
phone survey asked 56,154 residents the following
question: "Are you currently suffering from severe fatigue,
extreme tiredness, or exhaustion that has been present for
a period of one month or longer?" A total of 3,528
fatigued and 3,654 non-fatigued subjects were asked to
participate in a detailed telephone interview to assess CFS
case-defining criteria and other characteristics. Persons
fatigued for ≥ 6 months, not feeling better after rest, not
reporting any fatigue-associated medical or psychiatric
conditions, and reporting at least 4 of the 8 CFS symp-
toms were eligible to participate in a clinical evaluation.
These individuals were mailed a self-administered ques-
tionnaire requesting additional information about
fatigue, symptoms, and medical history. During the clinic
visit, subjects had a standardized physical examination
and laboratory tests of blood and urine samples adminis-
tered, and were given the Diagnostic Interview Scheduling
(DIS) for DSM-IV [8] to establish psychiatric diagnoses. A
physician review committee evaluated the clinical data
and classified subjects on the basis of 1994 CFS case-defi-
nition criteria [1] as having medical or psychiatric diag-
noses that could explain fatigue (permanent exclusions),
temporary medical conditions that required resolution
prior to classification (e.g., abnormal laboratory results,
pregnancy), insufficient fatigue severity or number of
symptoms, or CFS. Subjects who did not have any perma-
nent medical or psychiatric exclusion [7] were re-inter-
viewed yearly (4,228 in 1998, 3,980 in 1999, and 3,474 in
2000). Newly eligible subjects were invited for an initial
evaluation, and subjects who had previously come to the
clinic were invited for a follow-up visit. The physician
review committee again assessed CFS classification.
This study considered CFS subjects who were identified
during any year of the study and who had at least one fol-
low-up visit. Of note, none of the participants in the study
were informed of their CFS classification.
Changes in CFS classification
Changes in CFS classification at follow-up occurred
because case-defining criteria were no longer satisfied
(i.e., subjects reporting absence of fatigue, less than 4 of 8
symptoms, rest made fatigue a lot better, or fatigue did not
interfere a lot with work, educational, social/recreational,
or personal activities). Identification of alternative diag-
noses (permanent or temporary) also precluded CFS
classification.
Total remission was defined as having none of the case-
defining criteria (i.e., absence of fatigue, less than 4 symp-
toms, health did not interfere with activities). Partial
remission was defined as having some but not all of the
case-defining criteria. Total (partial) sustained remission
was defined as having two consecutive follow-up visits
with total (partial) remission.
Fatigue reduction between clinic visits
Although subjects might not have been in remission at the
follow-up clinic visit, they might have experienced at least
one episode of reduced fatigue between clinic visits. Sub-
jects at follow-up were asked "Since your last clinic visit,
has there ever been a time when you have felt less
fatigued?" Subjects reporting reduced fatigue were queried
as to how long the most recent episode had lasted,
whether they used any treatment since their previous
clinic visit, and whether they thought the treatment was
responsible for reducing their fatigue. Subjects who did
not report reduced fatigue were not asked questions about
treatment use.Health and Quality of Life Outcomes 2003, 1 http://www.hqlo.com/content/1/1/49
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Fatigue Assessment Instrument
Fatigued subjects also completed the 29-item Fatigue
Assessment Instrument [9] and scores were calculated for
four fatigue subscales: overall fatigue severity, situation-
specific fatigue (measuring fatigue sensitivity to particular
circumstances, such as heat, cold, and stress), fatigue con-
sequences (measuring loss of patience, motivation or abil-
ity to concentrate), and fatigue responsiveness to rest or
sleep.
Wellness scores, hours spent on activities and sleep during 
the past month
Subjects were asked the following questions referring to
their wellness and activities during the past month:
"Where would you place yourself in terms of energy, well-
ness, and ability to complete your every day activities on
a scale from 1 to 100?"; "On average, how many hours per
week did you spend on work duties, including working
from home and travel related to work; household chores,
such as cleaning, grocery shopping, and caring for your
family; activities such as hobbies, schooling, or volunteer
work?"; "How many hours of sleep, per day, including
naps, have you averaged during weekdays and on the
weekends?".
Statistical analyses
χ2, Fisher's exact and McNemar's tests were used to com-
pare proportions, and t-test and Wilcoxon test to compare
continuous variables. Repeated measures were analyzed
using generalizing estimating equations (GEE) models
[10] with the first-order autoregressive correlation struc-
ture. The association between the likelihood of reporting
a symptom and variables at initial classification (i.e., age
at initial classification, sex, race, education, income,
fatigue severity, wellness score, illness duration, onset
type, and age at onset) was determined by using the bino-
mial distribution with the logit link. Symptoms were
grouped as CFS symptoms (those in the CFS case defini-
tion [1]) or non-CFS symptoms (those not included in the
case definition). Models for the number of CFS or non-
CFS symptoms used the normal distribution with the
identity link. Logistic regression models were used to
determine predictors of remission. All tests were 2-sided
and p-values were considered significant if they did not
exceed 0.05. All analyses were conducted using SAS ver-
sion 8.1 (SAS Inc., Cary, NC).
Results
Characteristics at initial CFS classification
Among all fatigued subjects who came to the clinic over
the study period, 90 were identified with CFS (43 of 300
in 1997, 15 of 270 in 1998, 22 of 291 in 1999, and 10 of
217 in 2000). Of these, 65 (72.2%) had at least one fol-
low-up visit and thus were considered in this study. Tables
1,2,3,4 describe these subjects' characteristics at initial
classification. More than three-quarters of our sample self-
reported their onset as gradual and only 13.9% reported
ever being diagnosed or treated for CFS (Table 2). A diag-
nosis of depression was self-reported by 30.8% of the sub-
jects, but only 16.9% had lifetime major depression
disorder according to the DIS. The most prevalent CFS
symptom was unrefreshing sleep and the most prevalent
non-CFS symptom was problems getting to sleep (Table
3). More than 60% were currently employed, and only
16.9% reported unemployment due to the fatiguing ill-
ness (Table 4). Approximately 20% reported short dura-
tion of fatigue (≤ 2 years). Compared with published data
for CFS subjects [9], our sample had a significantly higher
mean for the situation-specific fatigue subscale (t-test p-
value = 0.0087) and a significantly lower mean for the
subscale indicating fatigue responsiveness to rest or sleep
(t-test p-value = 0.0167).
Follow-up visits
Of the 65 CFS subjects, 59 (90.8%), 39 (60%), and 24
(36.9%) were followed 1, 2, and 3 years, respectively, after
initial classification. Reasons for missing visits included
permanent exclusions in the previous visit, refusal to par-
ticipate, cancellation of clinic appointment, or loss to fol-
Table 2: Demographic characteristics of CFS subjects at initial 
classification (N = 65)
Characteristic Description
Female (%) 83.1








Hispanic origin (any race) (%) 1.5
Education beyond high school (%) 63.1






Current or most recent job (%)
Professional 20.3
Clerical work 20.3






Current living situation (%)
Alone 24.6
Couple with/without children 64.6
Single parent/living with family, friends 10.8Health and Quality of Life Outcomes 2003, 1 http://www.hqlo.com/content/1/1/49
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low-up (respondent moved or could not be located).
Subjects with follow-up visits had shorter duration of ill-
ness (median = 6 years vs. 9.1 years, Wilcoxon test p-value
= 0.0378), fewer non-CFS symptoms (mean = 4.9 vs. 6.2,
t-test p-value = 0.0419) and higher annual income (49.2%
vs. 20% above $40,000, χ2 test p-value = 0.0128) than
those who were not followed. No differences were found
with respect to age, sex, race, education, fatigue severity
scores, wellness scores, or number of CFS symptoms.
Symptoms
Using GEE models, it was determined that the mean
number of CFS and non-CFS symptoms decreased over
time compared with the number of symptoms at initial
classification (Table 3). Although the prevalence of CFS
symptoms also tended to decrease over time, the ranking
of symptoms remained the same. At all time points, unre-
freshing sleep, muscle pain, post-exertion fatigue, diffi-
culty thinking or memory impairment, and joint pain
were the 5 most prevalent symptoms; whereas headaches,
tender lymph nodes, and sore throat were the least preva-
lent symptoms.
Wellness, activities and sleep
Pairwise comparisons between consecutive time periods
indicated that wellness scores were higher at the first year
compared with initial evaluation (paired t-test p-value =
0.0085) (Table 3). No other significant differences were
detected.
At initial classification, the median number (interquartile
range) of hours spent on work duties, household chores,
recreational activities, and sleeping during the week and
during the weekend was, respectively, 40 (15–60), 15 (7–
20), 0 (0–5.5), 7 (6–8) and 8 (6–9). No significant
changes over time were detected.
Fatigue characteristics
Only a few fatigued subjects reported that rest relieved
fatigue at any follow-up period (Table 4). The proportion
of subjects reporting that fatigue interfered with social,
professional, or educational activities at 1-year follow-up
was significantly smaller than at initial classification
(McNemar's test p-values = 0.002, 0.0124, 0.0290, respec-
tively). Fatigue severity scores and number of activities
affected by fatigue were also significantly reduced at 1-
year follow-up (paired t-test p-values = 0.0047, 0.0001,
respectively). No other significant differences were
detected.
Illness states over time
About one-third of CFS subjects retained the classification
after 1 year of follow-up (Table 5). At 2 and 3 years follow-
up, only 21% of the subjects were classified as having CFS.
Most transitioned into a non-CFS state because of insuffi-
cient symptoms or fatigue severity, absence of fatigue, or
identification of an exclusionary condition. Overall,
23.1% (15 of 65) were eventually diagnosed with perma-
nent exclusions, of which the most common were sleep
disorders (i.e. sleep apnea or narcolepsy) (3 of 15), major
depressive disorder with melancholia (3 of 15) and
inflammatory bowel disease (2 of 15). Female sex,
income ≤ $40,000, older age at initial classification, and
higher fatigue severity scores were positively associated
with the eventual detection of an exclusionary condition
(Fisher's exact test p-values = 0.0197, 0.0169, and t-test p-
values = 0.0008, 0.0042, respectively). No deaths were
observed in this study.
Table 6 illustrates the pattern of illness states over the 3-
year follow-up period. Overall, 56.9% of the subjects (37
of 65) experienced partial or total remission by the end of
the follow-up. Among 40 subjects who had 2 consecutive
years of follow-up, 22.5% sustained partial remission and
10% sustained total remission. The 4 CFS subjects who
sustained total remission had been ill between 0.7 and
19.8 years and ranged in age from 35 to 53 years. There
were 3 individuals with gradual and 1 with sudden onset,
2 females, 3 whites, and 1 Hispanic. Only 3 (7.5%) of 40
subjects sustained the CFS classification over two consec-
utive follow-up visits.
Table 3: Clinical characteristics of CFS subjects at initial 
classification (N = 65)
Characteristic Description
Age at onset (mean, standard deviation, range) in 
years
37.1 (11.0, 5–57)
Median proportion of life with illness* 13.0
Self reported onset type (%)
Gradual 76.9
Sudden 20.0
Don't know/declined reply 3.1




Median (interquartile range) 27 (24–31)
Ever been diagnosed or treated by a physician (%)
Fibrositis or fibromyalgia 32.3
Depression 30.8
Allergies confirmed by formal testing 21.5
Irritable bowel syndrome 18.5
Temporomandibular joint syndrome 16.9
CFS 13.9
Environmental sensitivity disease 1.5
Yeast infection (only females) 48.2
Diagnostic Interview Schedule (%)
Current/Lifetime somatization 0
Lifetime major depression disorder 16.9
* Ratio between illness duration (in years) and age (in years)Health and Quality of Life Outcomes 2003, 1 http://www.hqlo.com/content/1/1/49
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Reduced fatigue between visits and treatments used
Thirty-two (54.2%) of 59, 23 (59%) of 39 and 11 (45.8%)
of 24 subjects followed at 1, 2, and 3 years, respectively,
reported that they felt less fatigued since the last visit.
More than half of the subjects reporting reduced fatigued
experienced at least 6 periods (53.1%, 65.2%, and 63.6%
at 1, 2, and 3 years, respectively) of reduced fatigue. The
median duration of the most recent period was 8 days for
years 1 and 2, and 30 days for year 3 of follow-up. Fatigue
reduction was not significantly associated with remission
at the follow-up visit.
Although traditional medicine was the most common
treatment among subjects reporting reduced fatigue
(100%, 91.7%, and 81.8% at 1, 2, and 3 years, respec-
tively, Table 7), only 20% reported using it exclusively.
Most subjects reported a combination of traditional med-
icine, self-help strategies, and complementary and alter-
native medicine therapies (84.4%, 73.9%, and 63.6% at 1,
2, and 3 years, respectively). More than 35% of the sub-
jects reported use of any complementary and alternative
medicine at any point in time and at least 50% of those
who used it thought that it reduced their fatigue (Table 7).
Remission was not associated with any particular
treatment.
Predictors of remission and symptom changes
To determine predictors of remission and symptoms, we
considered only the 50 subjects who never developed a
permanent exclusion. Sixty-two percent of these subjects
ever experienced a partial or total remission. There was no
association between the report of ever being diagnosed or
treated for CFS and remission (Fisher's exact test p-value =
1.0). Higher fatigue severity scores and larger total
number of symptoms were negatively associated with ever
experiencing remission. Odds ratios (OR) and 95%
confidence intervals (CI) from a multivariate logistic
regression model were, respectively, 0.389 (0.156–0.971)
and 0.724 (0.533–0.985). Subjects who eventually remit-
ted tended to have fewer symptoms at initial classification









CFS symptoms lasting ≥ 6 months (%)
Unrefreshing sleep 95.4 88.1 89.7 79.2*
Muscle aches or muscle pain 92.3 74.6* 74.4* 66.7*
Unusual fatigue post-exertion 78.5 50.9* 53.9* 33.3*
Difficulty thinking/concentrating or memory problems 76.9 71.2 59.0 62.5
Pain in joints 73.9 64.4 64.1 66.7
Severe headaches 58.5 35.6* 41.0 29.2*
Tender lymph nodes 16.9 20.3 12.8 4.2
Sore throat 12.3 6.8 5.3 0.0
Number of CFS symptoms (%)
0 0.0 1.7 7.7 4.2
1–3 0.0 32.2 25.6 50.0
7–8 7.7 10.2 2.6 0.0
Mean number (standard deviation) 5 (1.1) 4.1 (1.7)* 4.0 (1.7)* 3.4 (1.5)*
Non-CFS symptoms lasting ≥ 6 months (%)‡
Problems getting to sleep or waking up early in the morning 81.4 69.5 74.4 75.0
General weakness 80.0 61.0* 74.4 50.0*
Sinus or nasal problems 67.7 50.9* 53.9 58.3
Sensitivity to light 56.9 52.5 59.0 58.3
Depression 49.2 44.1 38.5 37.5
Numbness or tingling 35.9 44.8 30.8 58.3*
Shortness of breath 35.4 27.1 23.1 45.8
Stomach or abdominal pain 24.6 30.5 28.2 13.0
Diarrhea 20.0 20.3 20.5 4.2
Chills 18.8 13.6 5.1 4.2
Nausea 12.3 6.8 5.1 4.2
Fever 12.3 6.8 0.0 0.0
Mean number (standard deviation) 4.9 (2.0) 4.3 (2.2)* 4.1 (2.1) 4.1 (1.9)
Total CFS and non-CFS symptoms, mean (standard deviation) 10 (2.5) 8.4 (3.5)* 8.1 (3.5)* 7.5 (2.9)*
Wellness scores, mean (standard deviation) 41.2 (17.3) 48.5 (20.7)† 46.8 (20.5) 50.4 (17.6)
*p < 0.05 in GEE models compared with values at T0 † p < 0.05 in paired t-test ‡ Symptoms not included in CFS Case DefinitionHealth and Quality of Life Outcomes 2003, 1 http://www.hqlo.com/content/1/1/49
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but this trend was not statistically significant. Among the
32 subjects with at least two visits, 25% sustained partial
remission and 12.5% total remission. By using categories
of illness duration of ≤ 2 years, 2.1–10 years, and >10
years, it was found that subjects ill for 2.1–10 years were
less likely to sustain remission than subjects ill for ≤ 2
years (OR = 0.107, 95% CI = 0.013–0.88). Subjects ill for
>10 years were also less likely to sustain remission than
those with shorter duration of illness, but this trend was
not statistically significant (OR = 0.625, 95% CI = 0.073–
5.350). No other variables were associated with sustained
remission.
Few variables at initial classification were univariately
associated with the likelihood of reporting individual
symptoms (data available from the authors). Unrefresh-
ing sleep was associated with female sex, being white, hav-
ing higher fatigue severity scores, and being ill for 2.1–10
years when compared with 2 years or less. In a multivari-
ate GEE model for unrefreshing sleep including these var-
iables, being white, fatigue severity, and illness duration
remained significant (p-values = 0.0005, 0.0003, 0.0058,
respectively). The number of CFS symptoms was posi-
tively associated with higher fatigue severity scores (p-
value = 0.0043), but the number of non-CFS symptoms
was not associated with any variable.









Fatigue duration in years (%)
#2 18.5 2.0 0.0 0.0
2.1–5 23.1 20.4 27.6 11.1
5.1–10 30.8 34.7 31.0 44.4
>10 27.7 42.9 41.4 44.4
Median (interquartile range) 6 (3.6–10.8) 7.5 (5.3–13.2) 8.0 (4.8–12.9) 9.4 (7.2–13.9)
Rest did not relieve fatigue a lot (%) 100 95.2 96.6 94.4
Since fatiguing illness began, it interfered a lot with (%)
Social activities 76.9 51.0* 62.1 44.4
Personal activities 76.9 69.4 58.6 55.6
Work activities 66.2 42.9* 55.2 33.3
Educational activities 40 28.6* 27.6 27.8
Median number of activities affected by fatigue 3 2† 3 1.5
Currently employed (%) 63.1 61.2 55.2 55.6
Unemployed because of fatiguing illness (%) 16.9 18.4 13.8 16.7
Fatigue Assessment Instrument subscales, mean (standard 
deviation)
Severity 5.9 (0.9) 5.6 (0.8) † 5.8 (0.8) 5.4 (1.0)
Situation Specific 4.3 (1.3) ‡ 4.3 (1.5) 4.5 (1.4) 3.8 (1.4)
Psychological consequences 6.0 (1.0) 6.0 (1.1) 6.2 (0.7) 5.8 (0.9)
Responds to rest/sleep 3.8 (1.8) ‡ 3.3 (1.7) 3.8 (2.0) 3.4 (1.9)
* p < 0.05 in McNemar's test † p < 0.01 in paired t-test ‡ p < 0.05 in t-test, compared with published data
Table 6: Changes in CFS classification (%)
Classification 1-year follow-up (N = 59) 2-years follow-up (N = 39) 3-years follow-up (N = 24)
CFS 32.2 20.5 20.8
Insufficient symptoms or fatigue severity 30.5 30.8 37.5
Not fatigued 15.3 18.0 20.8
Exclusionary conditions
Permanent medical or psychiatric* 8.5 15.4 16.7
Temporary medical† 13.6 15.4 4.2
*Permanent exclusions include bulimia, bipolar disease, chronic hepatitis, body mass index = 47, Sjögren's syndrome, diabetes with complications, 
multiple sclerosis, inflammatory bowel disease (2 subjects), sleep apnea or narcolepsy (3 subjects) and major depressive disorder with melancholia 
(3 subjects) † Temporary exclusions include abnormal urinalysis, beta-blocker medication, results for positive Romberg's test, rheumatoid factor, 
abnormal liver function, hypertension, breast mass, multiple myeloma, and thyroid disease.Health and Quality of Life Outcomes 2003, 1 http://www.hqlo.com/content/1/1/49
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Discussion
Our data revealed a complex and intermittent pattern of
illness over time, where persistent CFS was the exception
and not the rule. We found that 20%-33% of the origi-
nally identified CFS subjects remained in the CFS state at
any subsequent visit, and only 7.5% remained in the CFS
state for two consecutive periods. Although 56.9% experi-
enced remission at some point during follow-up, only
22.5% sustained partial and 10% sustained total remis-
sion for two consecutive periods. We believe the apparent
discrepancy between the low proportion of subjects who
consistently fulfilled CFS criteria over time and the simi-
larly low proportion that sustained total remission may
reflect characteristics of the study design. Persons were
classified as CFS only if they satisfied all criteria at the time
of their clinical evaluation. Thus, individuals who met cri-
teria shortly before evaluation but had temporarily
improved around the time of their appointment (i.e.,
reported insufficient symptoms or fatigue severity) were
not classified as having CFS. Clinical diagnosis is probably
less conservative and practitioners would have continued
to endorse CFS in such persons over time.
Table 7: Illness states for CFS subjects at follow-up
No. of subjects 1-year follow-up (N = 59) 2-years follow-up (N = 39) 3-years follow-up (N = 24)
10 CFS No visit No visit
1 CFS No visit CFS
1 CFS CFS No visit
2 CFS Partial Remission No visit
1 CFS Partial Remission No visit
1 CFS Partial Remission CFS
1 CFS Temporary exclusion Partial Remission
1 CFS Permanent exclusion -
1 CFS Permanent exclusion -
3 Partial Remission No visit No visit
3 Partial Remission CFS No visit
1 Partial Remission CFS CFS
1 Partial Remission CFS Partial Remission
1 Partial Remission CFS Temporary exclusion
2 Partial Remission Partial Remission No visit
1 Partial Remission Partial Remission CFS
2 Partial Remission Partial Remission Partial Remission
1 Partial Remission Partial Remission Partial Remission
1 Partial Remission Partial Remission Permanent exclusion
2 Partial Remission Temporary exclusion Partial Remission
1 Partial Remission Temporary exclusion Permanent exclusion
3 Partial Remission Total Remission Total Remission
1 Total Remission No visit Partial Remission
1 Total Remission Permanent exclusion -
2 Total Remission Permanent exclusion -
1 Total Remission Total Remission No visit
5 Temporary exclusion No visit No visit
1 Temporary exclusion Partial Remission No visit
1 Temporary exclusion Temporary exclusion No visit
1 Temporary exclusion Temporary exclusion Partial Remission
3 Permanent exclusion - -
1 Permanent exclusion - -
1 Permanent exclusion - -
1 No visit No visit Permanent exclusion
1 No visit CFS CFS
1 No visit Partial Remission Partial Remission
1 No visit Partial Remission Partial Remission
1 No visit Partial Remission Permanent exclusion
1 No visit Permanent exclusion -
% Partial remission 37.3 38.5 45.8
% Total remission 8.5 10.3 12.5Health and Quality of Life Outcomes 2003, 1 http://www.hqlo.com/content/1/1/49
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Permanent exclusions were identified in 23.1% of the
subjects by the end of follow-up. Sleep apnea or nar-
colepsy and major depression disorder with melancholia
were the most prevalent (20%). This proportion was
remarkably higher than clinic-based studies that report
rates between 2% and 13% [2]. This discrepancy may be
due to the different case ascertainment approaches in clin-
ical and population-based settings. Clinic-based studies
reflect subjects seen at referral clinics who have generally
been triaged and well evaluated to rule out known exclu-
sionary conditions. In contrast, persons in our study rep-
resented the occurrence of the illness in the Wichita
population. Since only 13.9% had ever been treated or
diagnosed with CFS, the majority had either not perceived
their status as an illness or had not undergone evaluation
for identifiable causes of fatigue. Thus, it is not surprising
that by yearly examination of our participants, we identi-
fied a high proportion of medical or psychiatric exclu-
sions. In any event, this highlights the importance of
health care providers consistently following their patients
over time so that diseases can be promptly recognized and
treated.
Most studies that describe the clinical course of CFS are set
in hospitals or specialty clinics and include chronically ill
patients. These subjects usually experience a poor out-
come. Some investigators have suggested that subjects
from primary care clinics or the general population might
have better prognosis [11]. Contrary to these expectations,
our population-based remission rates were within the
range of those published in the literature of clinical stud-
ies [2–6]. Illness duration was the only predictor of sus-
tained remission and this effect could be detected only
when we defined categories of duration. Subjects with
shorter duration of illness (≤ 2 years) were more likely to
sustain remission than subjects ill for a longer time. It thus
seems important to consider the possibility that the effect
on clinical course outcomes is not the same for each addi-
tional illness duration year. Failure to define clinically
meaningful categories may explain inconsistent associa-
tions across studies. Finally, in agreement with other stud-
ies [2], no deaths occurred in our sample.
We found a steady decrease in the number of CFS symp-
toms over time. However, unrefreshing sleep, the most
common and persistent symptom at all follow-up peri-
ods, was still reported by 79.2% of subjects at the end of
follow-up. Unrefreshing sleep was also one of the most
commonly reported symptoms (87.5%) in another popu-
lation-based study [12]. Of interest, subjects reported
sleeping a median of 7 hours on weekdays. Thus,
although hours of sleep were within normal limits, sub-
jects found their sleep non-restorative. This observation
has also been noted in a study of sleep, using polysom-
nography, in CFS patients who slept an average of 7 hours
per night but reported feeling unrefreshed on waking [13].
We found decreased fatigue severity scores at the 1-year
follow-up, but these levels were still significantly higher
than values for normal fatigued controls [9]; thus, from a
practical standpoint, subjects remained severely fatigue
throughout the follow-up period. Despite this observa-
tion, our sample was highly functional (e.g., approxi-
mately 60% remained currently employed and worked a
Table 8: Treatment use and perception that the treatment was responsible for reduced fatigue at follow-up
Treatment % reporting treatment use among
subjects reporting reduced fatigue*
% believing treatment responsible for
reduced fatigue among subjects reporting use
1-year 2-years 3-years 1-year 2-years 3-years
Any traditional medicine 100.0 91.7 81.8 84.4 54.6 77.8
Medical doctor, emergency room 71.9 73.9 63.6 34.8 23.5 57.1
Prescription medication 78.1 69.6 63.6 64.0 37.5 71.4
Over-the-counter medication 65.6 65.2 27.3 42.9 26.7 100.0
Psychotherapy, counseling 12.5 13.0 9.1 50.0 33.3 100.0
Vitamins 81.3 69.6 72.7 65.4 56.3 62.5
Any self-help strategy 78.1 73.9 54.6 68.0 41.2 83.3
Exercise 68.8 65.2 54.6 63.6 33.3 83.3
Changes in diet 53.1 34.8 27.3 58.8 50.0 66.7
Any complementary and alternative 
medicine therapy
37.5 39.1 36.4 50.0 77.8 100.0
Herbal remedies 34.4 30.4 27.3 45.5 71.4 100.0
Homeopathy 6.3 4.4 18.2 100.0 100.0 100.0
Behavior modification (biofeedback) 3.1 4.4 0.0 0.0 100.0 0.0
Acupuncture 15.6 4.4 18.2 60.0 0.0 50.0
* N = 32, 23, and 11 at 1, 2, and 3 years, respectivelyHealth and Quality of Life Outcomes 2003, 1 http://www.hqlo.com/content/1/1/49
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median of 40 hours per week) compared with other sam-
ples in published literature [3–6].
There is currently no standard treatment for CFS. A recent
systematic review [14] concluded that cognitive behaviour
therapy and graded exercise therapy have shown promis-
ing results in controlled trials that evaluated interventions
in CFS subjects. These therapies, however, are not widely
available to the general public. Although there is insuffi-
cient evidence that complementary and alternative medi-
cine therapies are effective [14], they are definitely more
accessible. In our study, almost 100% of our subjects who
felt less fatigued between clinic visits used traditional
medicine treatments, but more than 35% reported use of
complementary and alternative medicine therapies, such
as herbal remedies, homeopathy, biofeedback, and acu-
puncture. This figure is twice as high as the 1997 US
national prevalence estimate of 17.5% [15]. These thera-
pies might be more prevalent among CFS subjects than
the general population because of patients' desire to
improve their health status and their lack of success with
traditional approaches.
Our findings are limited by reduced sample size over time,
which was due to elimination of subjects with permanent
exclusionary conditions, refusals, or loss to follow-up.
These factors should be considered when estimating the
size of future longitudinal studies. In addition, we did not
have a standardized measure of improvement or recovery,
nor did we ask subjects whether they considered them-
selves partially or fully recovered. We created a definition
based on absence of CFS case-defining criteria. This defi-
nition did not assess any measurable change in physical or
mental function that could objectively indicate meaning-
ful recovery from a clinical standpoint. As with so many
other CFS parameters, it is fundamental that standardized
measures of recovery be developed so that ambiguities in
the clinical course of CFS are resolved. Last, most of our
subjects reported a gradual onset and long duration of ill-
ness. Given enough subjects with sudden onset and/or
short duration of illness, prognosis might have been quite
different.
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